Jagsonpal Operating Income vs Net Income Analysis

JAGSNPHARM   639.65  23.25  3.77%   
Jagsonpal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jagsonpal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jagsonpal Pharmaceuticals is a good investment. Please check the relationship between Jagsonpal Pharmaceuticals Operating Income and its Net Income accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Operating Income vs Net Income

Operating Income vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jagsonpal Pharmaceuticals Operating Income account and Net Income. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Jagsonpal Pharmaceuticals' Operating Income and Net Income is 0.92. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Net Income in the same time period over historical financial statements of Jagsonpal Pharmaceuticals Limited, assuming nothing else is changed. The correlation between historical values of Jagsonpal Pharmaceuticals' Operating Income and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Jagsonpal Pharmaceuticals Limited are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Operating Income i.e., Jagsonpal Pharmaceuticals' Operating Income and Net Income go up and down completely randomly.

Correlation Coefficient

0.92
Relationship DirectionPositive 
Relationship StrengthVery Strong

Operating Income

Operating Income is the amount of profit realized from Jagsonpal Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Jagsonpal Pharmaceuticals Limited is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Jagsonpal Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Jagsonpal Pharmaceuticals Limited operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most indicators from Jagsonpal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jagsonpal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jagsonpal Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
The Jagsonpal Pharmaceuticals' current Selling General Administrative is estimated to increase to about 72.9 M, while Tax Provision is projected to decrease to under 38.7 M.
 2021 2022 2023 2024 (projected)
Interest Expense2.6M4.1M8.1M7.7M
Depreciation And Amortization15.3M11.8M16.6M14.6M

Jagsonpal Pharmaceuticals fundamental ratios Correlations

-0.230.34-0.070.91-0.33-0.080.78-0.1-0.370.070.77-0.470.2-0.14-0.780.51-0.06-0.220.9-0.310.170.09-0.31-0.78-0.29
-0.23-0.620.55-0.580.870.9-0.44-0.570.610.27-0.490.82-0.080.340.12-0.43-0.20.94-0.470.94-0.07-0.61-0.250.30.72
0.34-0.620.110.5-0.42-0.570.470.42-0.31-0.240.4-0.460.05-0.74-0.170.320.05-0.510.4-0.450.050.320.36-0.33-0.55
-0.070.550.11-0.350.670.34-0.18-0.040.690.18-0.380.49-0.07-0.560.16-0.29-0.320.69-0.410.7-0.050.03-0.070.360.29
0.91-0.580.5-0.35-0.63-0.390.790.08-0.59-0.020.82-0.690.16-0.2-0.670.580.03-0.590.96-0.630.120.24-0.18-0.77-0.48
-0.330.87-0.420.67-0.630.74-0.65-0.420.860.17-0.720.89-0.420.090.22-0.68-0.130.93-0.580.95-0.41-0.460.040.550.79
-0.080.9-0.570.34-0.390.74-0.3-0.870.390.36-0.330.78-0.030.410.1-0.39-0.160.75-0.260.8-0.02-0.81-0.390.050.81
0.78-0.440.47-0.180.79-0.65-0.30.07-0.650.020.91-0.680.58-0.2-0.640.69-0.09-0.490.76-0.560.560.23-0.38-0.85-0.57
-0.1-0.570.42-0.040.08-0.42-0.870.07-0.09-0.380.09-0.54-0.03-0.38-0.040.270.11-0.37-0.02-0.45-0.030.790.520.22-0.75
-0.370.61-0.310.69-0.590.860.39-0.65-0.09-0.08-0.780.68-0.54-0.140.24-0.62-0.170.78-0.660.76-0.52-0.020.070.740.65
0.070.27-0.240.18-0.020.170.360.02-0.38-0.08-0.040.220.05-0.030.27-0.39-0.240.180.080.220.05-0.16-0.25-0.060.13
0.77-0.490.4-0.380.82-0.72-0.330.910.09-0.78-0.04-0.780.66-0.01-0.710.79-0.02-0.580.8-0.660.640.15-0.23-0.94-0.61
-0.470.82-0.460.49-0.690.890.78-0.68-0.540.680.22-0.78-0.430.180.46-0.720.080.8-0.590.89-0.41-0.62-0.020.560.83
0.2-0.080.05-0.070.16-0.42-0.030.58-0.03-0.540.050.66-0.430.05-0.290.68-0.15-0.250.14-0.31.0-0.02-0.36-0.61-0.36
-0.140.34-0.74-0.56-0.20.090.41-0.2-0.38-0.14-0.03-0.010.180.05-0.13-0.070.230.18-0.040.110.05-0.5-0.09-0.10.29
-0.780.12-0.170.16-0.670.220.1-0.64-0.040.240.27-0.710.46-0.29-0.13-0.550.110.12-0.630.26-0.27-0.020.160.680.21
0.51-0.430.32-0.290.58-0.68-0.390.690.27-0.62-0.390.79-0.720.68-0.07-0.55-0.02-0.530.52-0.560.650.2-0.21-0.64-0.61
-0.06-0.20.05-0.320.03-0.13-0.16-0.090.11-0.17-0.24-0.020.08-0.150.230.11-0.02-0.150.08-0.19-0.14-0.050.38-0.01-0.11
-0.220.94-0.510.69-0.590.930.75-0.49-0.370.780.18-0.580.8-0.250.180.12-0.53-0.15-0.510.96-0.23-0.39-0.090.440.65
0.9-0.470.4-0.410.96-0.58-0.260.76-0.02-0.660.080.8-0.590.14-0.04-0.630.520.08-0.51-0.550.10.08-0.17-0.8-0.45
-0.310.94-0.450.7-0.630.950.8-0.56-0.450.760.22-0.660.89-0.30.110.26-0.56-0.190.96-0.55-0.29-0.51-0.090.50.72
0.17-0.070.05-0.050.12-0.41-0.020.56-0.03-0.520.050.64-0.411.00.05-0.270.65-0.14-0.230.1-0.29-0.01-0.35-0.58-0.35
0.09-0.610.320.030.24-0.46-0.810.230.79-0.02-0.160.15-0.62-0.02-0.5-0.020.2-0.05-0.390.08-0.51-0.010.10.15-0.64
-0.31-0.250.36-0.07-0.180.04-0.39-0.380.520.07-0.25-0.23-0.02-0.36-0.090.16-0.210.38-0.09-0.17-0.09-0.350.10.28-0.28
-0.780.3-0.330.36-0.770.550.05-0.850.220.74-0.06-0.940.56-0.61-0.10.68-0.64-0.010.44-0.80.5-0.580.150.280.36
-0.290.72-0.550.29-0.480.790.81-0.57-0.750.650.13-0.610.83-0.360.290.21-0.61-0.110.65-0.450.72-0.35-0.64-0.280.36
Click cells to compare fundamentals

Jagsonpal Pharmaceuticals Account Relationship Matchups

Jagsonpal Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.5B1.6B1.7B1.9B2.2B1.7B
Short Long Term Debt Total37.9M46.6M67.9M60.0M89.4M165.5M
Other Current Liab155.5M117.4M4.6M183.3M88.5M78.7M
Total Current Liabilities328.3M404.0M341.6M275.7M191.3M361.4M
Total Stockholder Equity1.1B1.2B1.3B1.6B1.9B1.2B
Property Plant And Equipment Net239.6M233.5M223.7M242.8M93.0M88.4M
Net Debt(334.1M)(518.4M)(251.4M)(50.5M)(38.2M)(36.3M)
Retained Earnings476.9M585.9M675.2M945.4M1.0B1.1B
Cash380.7M586.3M251.4M110.5M127.6M199.6M
Non Current Assets Total520.4M437.3M576.8M303.9M178.2M169.3M
Non Currrent Assets Other(353.8M)38.3M29.2M27.2M38.2M40.1M
Cash And Short Term Investments380.7M618.8M472.8M1.1B1.5B1.6B
Net Receivables224.5M126.6M155.8M221.1M109.5M104.0M
Liabilities And Stockholders Equity1.5B1.6B1.7B1.9B2.2B1.7B
Non Current Liabilities Total30.9M18.8M34.4M84.8M105.5M87.4M
Inventory293.3M297.2M297.4M206.8M150.0M247.3M
Other Current Assets274.5M143.6M80.6M41.9M363.2M381.4M
Total Liab359.2M422.7M376.0M360.6M296.8M350.2M
Total Current Assets949.1M1.2B1.1B1.6B2.0B1.1B
Accumulated Other Comprehensive Income(337.4M)1.1B496.9M506.5M588.7M618.2M
Short Term Debt64.0M67.9M7.5M7.5M13.8M13.1M
Accounts Payable117.1M180.5M185.5M78.5M76.0M96.0M
Current Deferred Revenue92.1M137.5M(7.5M)81.4M12.9M12.3M
Other Liab30.9M18.8M34.4M32.4M29.1M26.0M
Net Tangible Assets1.1B1.2B1.3B1.6B1.8B1.2B
Other Assets170.1M82.9M147.0M20.3M23.4M22.2M
Property Plant Equipment239.6M233.5M223.7M242.8M218.5M258.8M
Cash And Equivalents398.1M589.4M232.3M110.5M127.1M242.0M
Net Invested Capital1.2B1.3B1.3B1.6B1.9B1.5B
Net Working Capital620.8M800.8M766.2M1.4B1.8B1.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jagsonpal Stock

Balance Sheet is a snapshot of the financial position of Jagsonpal Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Jagsonpal Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jagsonpal Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jagsonpal currently owns. An asset can also be divided into two categories, current and non-current.